A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale
Indian Dermatology Online Journal · 2025-05 · 16 (3) · 420-425
DOI: 10.4103/idoj.idoj_665_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Dermatology Online Journal, online erschienen am 15.04.2025. Verfasst von Kabir Sardana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr. Ram Manohar Loh…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD. Aim and Objectives: To assess the effectiveness and adverse effect profile of tofacitinib in recalcitrant, moderate-to-severe AD patients and to compare the cost of therapy of tofacitinib with dupilumab. Patients and Methods: We retrospectively analyzed records of moderate to severe AD treated with tofacitinib monotherapy. The response to tofacitinib was assessed using clinical scores including Numerical Rating Scale (NRS), Scoring Atopic Dermatitis (SCORAD), and Eczema Area and Severity Index (EASI) at 4 weeks and 8 weeks of treatment. We also analyzed the duration of remission and time after which recurrences were seen after stopping tofacitinib. The cost of tofacitinib was compared with dupilumab.
Results
Twelve cases of recalcitrant moderate–severe AD who had failed systemic agents [oral corticosteroids (n = 7), cyclosporine (n = 4), and azathioprine (n = 2)] were treated with tofacitinib monotherapy. There was a statistically significant reduction in SCORAD, EASI, and NRS scores at 4 weeks and 8 weeks of tofacitinib therapy [mean at baseline: 4 weeks: 8 weeks = SCORAD- 43.54: 22.74: 11.87 ( P = 0.002); EASI-19.5: 6.45: 1.6 ( P = 0.002); NRS-5.75: 3.25: 1.08 ( P = 0.002)]. EASI 90 was achieved by 66% of patients in 8 weeks with treatment failure in one patient. The mean time to achieve complete/near complete resolution (n = 8) of the disease was 6.1 weeks (3-8 weeks). Relapse of the disease was noted in 4/11 (36.3%) patients. Side effects were observed in 5/12 (41.6%) patients (herpes zoster, dyslipidemia, anemia, impetigo, and thrombocytosis). The cost of therapy with dupilumab is 122 times higher than that of tofacitinib therapy (8 weeks treatment).
Limitations
Small sample size and lack of tissue cytokines analysis pre- and post-treatment.
Conclusion
Tofacitinib (pan JAK inhibitor) inhibits T helper 2 (Th2), Th1, Th17, and Th22 cell lines, and thus has potential for refractory AD. There is a need to generate tissue-based cytokine expression data in Indian patients with AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr. Ram Manohar Lohia Hospital, New Delhi, India.
ORCID-Profile: Kabir Sardana
Zitieren
APA
Sardana, K., Sharath, S., Meena, S. K., Khurana, A., & Dhir, B. (2025). A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale. Indian Dermatology Online Journal, 16(3), 420-425. https://doi.org/10.4103/idoj.idoj_665_24
Vancouver
Sardana K, Sharath S, Meena SK, Khurana A, Dhir B. A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale. Indian Dermatology Online Journal. 2025;16(3):420-425. doi:10.4103/idoj.idoj_665_24
BibTeX
@article{Sardana2025,
author = {Sardana, Kabir and Sharath, Savitha and Meena, Sumitra Kumari and Khurana, Ananta and Dhir, Bhawuk},
title = {A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale},
journal = {Indian Dermatology Online Journal},
year = {2025},
volume = {16},
number = {3},
pages = {420--425},
doi = {10.4103/idoj.idoj_665_24}
}
EUVIMED